| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
127,470,000 |
| Market
Cap: |
1.89(B) |
| Last
Volume: |
639,983 |
Avg
Vol: |
1,080,540 |
| 52
Week Range: |
$11.665 - $20.73 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile NeoGenomics operate a network of cancer-focused testing laboratories in the U.S., Europe and Asia. Co.'s testing services include the following: Cytogenetics (karyotype analysis), a study of chromosomes and their relationship to disease; Fluorescence In-Situ Hybridization, a molecular cytogenetic technique that focuses on detecting and localizing the presence or absence of specific DNA sequences and genes on chromosomes; Flow cytometry, a technique utilized to measure the characteristics of cell populations; Immunohistochemistry and Digital Imaging; Molecular testing; and Morphologic analysis, a process of analyzing cells under the microscope.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
6,112 |
8,699 |
11,368 |
11,368 |
| Total Sell Value |
$97,579 |
$136,292 |
$185,375 |
$185,375 |
| Total People Sold |
1 |
2 |
2 |
2 |
| Total Sell Transactions |
1 |
2 |
3 |
3 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Jones Steven C |
Executive Vice President |
• • – |
2018-11-12 |
4 |
S |
$16.66 |
$1,666,000 |
I/I |
(100,000) |
2,200,000 |
|
- |
|
| Balliet Jennifer |
VP and Chief Culture Officer |
• – – |
2018-11-12 |
4 |
S |
$16.73 |
$476,889 |
D/D |
(28,505) |
20,000 |
|
- |
|
| Shovlin Robert J. |
President, Clinical Services |
• – – |
2018-11-12 |
4 |
S |
$16.76 |
$611,623 |
D/D |
(36,493) |
123,391 |
|
- |
|
| Ge Medical Systems Information Technologies, Inc. |
10% Owner |
– – • |
2018-11-09 |
4 |
S |
$16.75 |
$69,761,321 |
I/I |
(4,164,855) |
10,835,145 |
|
- |
|
| Balliet Jennifer |
VP and Chief Culture Officer |
• – – |
2018-11-09 |
4 |
S |
$17.00 |
$677,076 |
D/D |
(39,828) |
48,505 |
|
- |
|
| Balliet Jennifer |
VP and Chief Culture Officer |
• – – |
2018-11-09 |
4 |
OE |
$0.00 |
$167,300 |
D/D |
68,333 |
88,333 |
|
- |
|
| Johnson Kevin C |
Director |
– • – |
2018-11-09 |
4 |
S |
$17.01 |
$1,124,180 |
D/D |
(66,007) |
77,866 |
|
- |
|
| Shovlin Robert J. |
President, Clinical Services |
• – – |
2018-11-09 |
4 |
S |
$17.05 |
$3,069,000 |
D/D |
(180,000) |
159,884 |
|
- |
|
| Shovlin Robert J. |
President, Clinical Services |
• – – |
2018-11-09 |
4 |
OE |
$4.79 |
$1,437,000 |
D/D |
300,000 |
339,884 |
|
- |
|
| Brodie Steven G. |
VP - Pharma Operations |
• – – |
2018-10-22 |
4 |
OE |
$3.45 |
$46,002 |
D/D |
13,334 |
45,953 |
|
- |
|
| Van Oort Douglas M |
Chairman and CEO |
• • – |
2018-08-03 |
4/A |
A |
$0.00 |
$0 |
D/D |
197,042 |
2,030,027 |
|
- |
|
| Van Oort Douglas M |
Chairman and CEO |
• • – |
2018-08-03 |
4/A |
D |
$0.00 |
$0 |
D/D |
(21,904) |
2,008,123 |
|
- |
|
| Van Oort Douglas M |
Chairman and CEO |
• • – |
2018-08-01 |
4 |
A |
$0.00 |
$0 |
D/D |
46,429 |
2,054,552 |
|
- |
|
| Jones Steven C |
Executive Vice President |
• • – |
2018-08-01 |
4 |
S |
$14.00 |
$1,679,272 |
I/I |
(119,948) |
2,300,000 |
|
- |
|
| Jones Steven C |
Executive Vice President |
• • – |
2018-07-31 |
4 |
S |
$14.00 |
$545,328 |
I/I |
(38,952) |
2,419,948 |
|
- |
|
| Jones Steven C |
Executive Vice President |
• • – |
2018-07-30 |
4 |
S |
$14.00 |
$624,811 |
I/I |
(44,600) |
2,458,900 |
|
- |
|
| Shovlin Robert J. |
President, Clinical Services |
• – – |
2018-06-29 |
4 |
S |
$13.12 |
$169,786 |
D/D |
(12,941) |
39,884 |
|
- |
|
| Jones Steven C |
Executive Vice President |
• • – |
2018-06-22 |
4 |
S |
$14.04 |
$1,259,220 |
I/I |
(89,688) |
2,500,000 |
|
- |
|
| Jones Steven C |
Executive Vice President |
• • – |
2018-06-19 |
4 |
S |
$13.32 |
$2,108,067 |
I/I |
(158,312) |
2,589,688 |
|
- |
|
| Jones Steven C |
Executive Vice President |
• • – |
2018-06-15 |
4 |
S |
$13.25 |
$26,500 |
I/I |
(2,000) |
2,748,000 |
|
- |
|
| Crowther Bruce K |
Director |
– • – |
2018-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
15,564 |
32,766 |
|
- |
|
| Jones Steven C |
Executive Vice President |
• • – |
2018-06-01 |
4 |
S |
$12.12 |
$2,794,060 |
I/I |
(230,533) |
2,750,000 |
|
- |
|
| Jones Steven C |
Executive Vice President |
• • – |
2018-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
6,897 |
241,815 |
|
- |
|
| Johnson Kevin C |
Director |
– • – |
2018-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
15,564 |
143,873 |
|
- |
|
| Hannah Alison L. |
Director |
– • – |
2018-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
15,564 |
61,013 |
|
- |
|
544 Records found
|
|
Page 13 of 22 |
|
|
0.19 (1.27%) 
